热门资讯> 正文

Beyond Air停止将NeuNOS子公司出售给XTL BiopharmPharmaceuticals

2026-03-10 19:59

Beyond Air, Inc.(XAIR) 0
Xtl生物制药(XTLB) 0

Beyond Air (XAIR) has terminated an agreement with XTL Biopharmaceuticals to sell its majority ownership interest in NeuroNOS subsidiary
The companies had entered into a letter of intent in January 2026. The letter of intent expired on March 9, 2026, in accordance with its terms, and the parties did not enter into a definitive agreement.
XAIR +4.40% premarket to $0.8968.
Source: Press Release

More on Beyond Air

Beyond Air Q3 2026 Earnings Preview
Beyond Air appoints Dan Moorhead as CFO
Seeking Alpha’s Quant Rating on Beyond Air
Historical earnings data for Beyond Air

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。